The study showed that 6.6% of the sarcoma patients carried either known pathogenic, likely pathogenic or novel loss of function variants in genes known to be relevant to cancer predisposition, such as TP53, ATM, BRCA2, BRCA1 and CDKN2B [35]. This evidence concerns the gene TP53 and sarcoma.